国产一区一二区高清不卡,国产一区二区最新免费视频,51日日夜夜精品视频,日日夜夜精品视频天天7799,五月伊人国语,国产一区视频,7777无码少妇一区二区三区,五月伊人国语,7799精彩视频天天看网站,国产精品无码久久久久av,永久入口,91成品人网页进入入口,欧美 日韩 中文字幕 高清,妖精视频一区二区三区亚洲,精品亚洲永久免费精品导航,久久久国产一区二区三区,天天中文综合

In the United States, the primary regulatory authorities for Clinical Trial Reports are:

1. Food and Drug Administration (FDA)

• Role: The FDA is the main regulatory body overseeing clinical trials for drugs, biologics, and medical devices. It reviews Clinical Trial Reports as part of the New Drug Application (NDA), Biologics License Application (BLA), or Premarket Approval (PMA) process.
• Website: FDA

2. Institutional Review Boards (IRBs)

• Role: IRBs review and approve clinical trial protocols and ensure that trials are conducted ethically and that participants' rights are protected. They are not regulatory bodies but play a crucial role in the oversight of clinical trials.
• Website: Office for Human Research Protections (OHRP)

3. National Institutes of Health (NIH)

• Role: While not a regulatory body, the NIH supports and funds clinical trials and requires the submission of trial results and reports for its funded studies. It also maintains the ClinicalTrials.gov registry, where trial results are often posted.
• Website: NIH

4. Centers for Medicare & Medicaid Services (CMS)

• Role: For trials involving medical devices or interventions covered by Medicare or Medicaid, CMS may be involved in evaluating the effectiveness and outcomes of these interventions.
• Website: CMS

These authorities ensure that clinical trials are conducted according to regulatory standards and that the results are thoroughly reviewed and reported

Contact Us：

Whatsapp or Wechat：+86 15816864648；email address：hito.lin@grzan.cn